$
0.328
0.000(0.000%)
  • Overview
  • Forecast
  • Valuation
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.3279
Open
0.3279
VWAP
0.33
Vol
1.36K
Mkt Cap
29.63M
Low
0.3279
Amount
446.27
EV/EBITDA(TTM)
--
Total Shares
88.54M
EV
-25.62M
EV/OCF(TTM)
--
P/S(TTM)
--
Allakos Inc. is a clinical-stage biotechnology company, which is engaged in the development of therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. The Company’s most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It is developing AK006 for the treatment of CSU and potentially other indications. AK006 has completed preclinical testing, and in these studies, it has demonstrated that binding of AK006 to Siglec-6 inhibits multiple modes of mast cell activation, including IgE, IL-33, KIT, C5a and MRGPR-X2. In addition to mast cell inhibition, AK006 reduced human tissue mast cells via ADCP in the presence of activated macrophages. The Company is also developing lirentelimab (AK002) and, in conjunction with the Phase II, lirentelimab results in atopic dermatitis and chronic spontaneous urticaria.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
--
--
-0.020
-92.39%
--
--
-0.020
-90.48%
--
--
-0.190
-36.67%
Estimates Revision
Stock Price
Go Up
up Image
+20.07%
In Past 3 Month
1 Analyst Rating
up Image
21.99% Upside
Wall Street analysts forecast ALLK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALLK is 0.40 USD with a low forecast of 0.40 USD and a high forecast of 0.40  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
up Image
21.99% Upside
Current: 0.328
sliders
Low
0.40
Averages
0.40
High
0.40
JMP Securities
Jonathan Wolleben
Buy
Reiterates
$3
2024-09-26
Reason
Jefferies
Kevin Strang
Hold
Maintains
$1.5 → $1
2024-07-18
Reason
JMP Securities
Jonathan Wolleben
Buy
Reiterates
$3
2024-06-26
Reason
Cantor Fitzgerald
Jennifer Kim
Hold
Reiterates
n/a
2024-06-20
Reason

Valuation Metrics

The current forward P/E ratio for Allakos Inc (ALLK.O) is -0.63, compared to its 5-year average forward P/E of -8.19. For a more detailed relative valuation and DCF analysis to assess Allakos Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.19
Current PE
-0.63
Overvalued PE
1.71
Undervalued PE
-18.09

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-7.56
Current EV/EBITDA
0.89
Overvalued EV/EBITDA
3.34
Undervalued EV/EBITDA
-18.46

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

Annual
Quarterly
FY2025Q1
YoY :
-41.58%
-26.71M
Operating Profit
FY2025Q1
YoY :
-63.20%
-26.18M
Net Income after Tax
FY2025Q1
YoY :
-64.20%
-0.29
EPS - Diluted
FY2025Q1
YoY :
-12.46%
-28.49M
Free Cash Flow

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
87.9K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
62.7K
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
746.5K
Volume
2
Bought
0-3
0
0.0
Volume
Months
3-6
2
1.8M
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

ALLK News & Events

Events Timeline

2025-04-02 (ET)
2025-04-02
08:03:14
Allakos to be acquired by Concentra Biosciences for 33c per share in cash
select
2025-03-12 (ET)
2025-03-12
16:05:30
Allakos reports Q4 EPS 0c, consensus (18c)
select
2025-01-27 (ET)
2025-01-27
08:05:53
Allakos to discontinue further clinical development of AK006, cut workforce 75%
select
Sign Up For More Events

News

7.0
04-04PRnewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COOP, HMST, ALLK, OPOF on Behalf of Shareholders
8.5
04-02SeekingAlpha
Allakos surges on reverse merger deal with Concentra Biosciences
7.0
04-02Globenewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COOP, RDFN, ALLK on Behalf of Shareholders
Sign Up For More News

FAQ

arrow icon

What is Allakos Inc (ALLK) stock price today?

The current price of ALLK is 0.3279 USD — it has increased 0 % in the last trading day.

arrow icon

What is Allakos Inc (ALLK)'s business?

arrow icon

What is the price predicton of ALLK Stock?

arrow icon

What is Allakos Inc (ALLK)'s revenue for the last quarter?

arrow icon

What is Allakos Inc (ALLK)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Allakos Inc (ALLK)'s fundamentals?

arrow icon

How many employees does Allakos Inc (ALLK). have?

arrow icon

What is Allakos Inc (ALLK) market cap?